Direct maternal morbidity and the risk of pregnancy-related deaths, stillbirths, and neonatal deaths in South Asia and sub-Saharan Africa: A population-based prospective cohort study in 8 countries.
Adolescent
Adult
Africa South of the Sahara
/ epidemiology
Asia
/ epidemiology
Female
Humans
Infant
Infant Mortality
Infant, Newborn
Maternal Mortality
Pregnancy
Pregnancy Complications
/ diagnosis
Pregnancy Outcome
Prospective Studies
Risk Assessment
Risk Factors
Stillbirth
/ epidemiology
Young Adult
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
11
2020
accepted:
04
05
2021
revised:
13
07
2021
pubmed:
29
6
2021
medline:
5
10
2021
entrez:
28
6
2021
Statut:
epublish
Résumé
Maternal morbidity occurs several times more frequently than mortality, yet data on morbidity burden and its effect on maternal, foetal, and newborn outcomes are limited in low- and middle-income countries. We aimed to generate prospective, reliable population-based data on the burden of major direct maternal morbidities in the antenatal, intrapartum, and postnatal periods and its association with maternal, foetal, and neonatal death in South Asia and sub-Saharan Africa. This is a prospective cohort study, conducted in 9 research sites in 8 countries of South Asia and sub-Saharan Africa. We conducted population-based surveillance of women of reproductive age (15 to 49 years) to identify pregnancies. Pregnant women who gave consent were include in the study and followed up to birth and 42 days postpartum from 2012 to 2015. We used standard operating procedures, data collection tools, and training to harmonise study implementation across sites. Three home visits during pregnancy and 2 home visits after birth were conducted to collect maternal morbidity information and maternal, foetal, and newborn outcomes. We measured blood pressure and proteinuria to define hypertensive disorders of pregnancy and woman's self-report to identify obstetric haemorrhage, pregnancy-related infection, and prolonged or obstructed labour. Enrolled women whose pregnancy lasted at least 28 weeks or those who died during pregnancy were included in the analysis. We used meta-analysis to combine site-specific estimates of burden, and regression analysis combining all data from all sites to examine associations between the maternal morbidities and adverse outcomes. Among approximately 735,000 women of reproductive age in the study population, and 133,238 pregnancies during the study period, only 1.6% refused consent. Of these, 114,927 pregnancies had morbidity data collected at least once in both antenatal and in postnatal period, and 114,050 of them were included in the analysis. Overall, 32.7% of included pregnancies had at least one major direct maternal morbidity; South Asia had almost double the burden compared to sub-Saharan Africa (43.9%, 95% CI 27.8% to 60.0% in South Asia; 23.7%, 95% CI 19.8% to 27.6% in sub-Saharan Africa). Antepartum haemorrhage was reported in 2.2% (95% CI 1.5% to 2.9%) pregnancies and severe postpartum in 1.7% (95% CI 1.2% to 2.2%) pregnancies. Preeclampsia or eclampsia was reported in 1.4% (95% CI 0.9% to 2.0%) pregnancies, and gestational hypertension alone was reported in 7.4% (95% CI 4.6% to 10.1%) pregnancies. Prolonged or obstructed labour was reported in about 11.1% (95% CI 5.4% to 16.8%) pregnancies. Clinical features of late third trimester antepartum infection were present in 9.1% (95% CI 5.6% to 12.6%) pregnancies and those of postpartum infection in 8.6% (95% CI 4.4% to 12.8%) pregnancies. There were 187 pregnancy-related deaths per 100,000 births, 27 stillbirths per 1,000 births, and 28 neonatal deaths per 1,000 live births with variation by country and region. Direct maternal morbidities were associated with each of these outcomes. Our findings imply that health programmes in sub-Saharan Africa and South Asia must intensify their efforts to identify and treat maternal morbidities, which affected about one-third of all pregnancies and to prevent associated maternal and neonatal deaths and stillbirths. The study is not a clinical trial.
Sections du résumé
BACKGROUND
Maternal morbidity occurs several times more frequently than mortality, yet data on morbidity burden and its effect on maternal, foetal, and newborn outcomes are limited in low- and middle-income countries. We aimed to generate prospective, reliable population-based data on the burden of major direct maternal morbidities in the antenatal, intrapartum, and postnatal periods and its association with maternal, foetal, and neonatal death in South Asia and sub-Saharan Africa.
METHODS AND FINDINGS
This is a prospective cohort study, conducted in 9 research sites in 8 countries of South Asia and sub-Saharan Africa. We conducted population-based surveillance of women of reproductive age (15 to 49 years) to identify pregnancies. Pregnant women who gave consent were include in the study and followed up to birth and 42 days postpartum from 2012 to 2015. We used standard operating procedures, data collection tools, and training to harmonise study implementation across sites. Three home visits during pregnancy and 2 home visits after birth were conducted to collect maternal morbidity information and maternal, foetal, and newborn outcomes. We measured blood pressure and proteinuria to define hypertensive disorders of pregnancy and woman's self-report to identify obstetric haemorrhage, pregnancy-related infection, and prolonged or obstructed labour. Enrolled women whose pregnancy lasted at least 28 weeks or those who died during pregnancy were included in the analysis. We used meta-analysis to combine site-specific estimates of burden, and regression analysis combining all data from all sites to examine associations between the maternal morbidities and adverse outcomes. Among approximately 735,000 women of reproductive age in the study population, and 133,238 pregnancies during the study period, only 1.6% refused consent. Of these, 114,927 pregnancies had morbidity data collected at least once in both antenatal and in postnatal period, and 114,050 of them were included in the analysis. Overall, 32.7% of included pregnancies had at least one major direct maternal morbidity; South Asia had almost double the burden compared to sub-Saharan Africa (43.9%, 95% CI 27.8% to 60.0% in South Asia; 23.7%, 95% CI 19.8% to 27.6% in sub-Saharan Africa). Antepartum haemorrhage was reported in 2.2% (95% CI 1.5% to 2.9%) pregnancies and severe postpartum in 1.7% (95% CI 1.2% to 2.2%) pregnancies. Preeclampsia or eclampsia was reported in 1.4% (95% CI 0.9% to 2.0%) pregnancies, and gestational hypertension alone was reported in 7.4% (95% CI 4.6% to 10.1%) pregnancies. Prolonged or obstructed labour was reported in about 11.1% (95% CI 5.4% to 16.8%) pregnancies. Clinical features of late third trimester antepartum infection were present in 9.1% (95% CI 5.6% to 12.6%) pregnancies and those of postpartum infection in 8.6% (95% CI 4.4% to 12.8%) pregnancies. There were 187 pregnancy-related deaths per 100,000 births, 27 stillbirths per 1,000 births, and 28 neonatal deaths per 1,000 live births with variation by country and region. Direct maternal morbidities were associated with each of these outcomes.
CONCLUSIONS
Our findings imply that health programmes in sub-Saharan Africa and South Asia must intensify their efforts to identify and treat maternal morbidities, which affected about one-third of all pregnancies and to prevent associated maternal and neonatal deaths and stillbirths.
TRIAL REGISTRATION
The study is not a clinical trial.
Identifiants
pubmed: 34181649
doi: 10.1371/journal.pmed.1003644
pii: PMEDICINE-D-20-05504
pmc: PMC8277068
doi:
Types de publication
Journal Article
Meta-Analysis
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003644Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
We have read the journal’s policy and the authors of this manuscript have the following competing interests: ZAB is a member of the Editorial Board of PLOS Medicine. Remaining authors declared no competing interests.
Références
BJOG. 2014 Mar;121 Suppl 1:76-88
pubmed: 24641538
Lancet Glob Health. 2018 Dec;6(12):e1297-e1308
pubmed: 30361107
J Clin Epidemiol. 2008 Feb;61(2):169-76
pubmed: 18177790
Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):999-1012
pubmed: 18819848
BJOG. 2012 May;119(6):653-61
pubmed: 22489760
J Obstet Gynaecol Can. 2010 Aug;32(8):730-8
pubmed: 21050503
Trop Med Int Health. 2013 Jun;18(6):712-24
pubmed: 23551357
Int J Gynaecol Obstet. 2018 May;141 Suppl 1:20-38
pubmed: 29851116
PLoS Med. 2019 Apr 12;16(4):e1002783
pubmed: 30978179
Stud Fam Plann. 1997 Sep;28(3):203-14
pubmed: 9322336
J Nutr. 2000 Nov;130(11):2675-82
pubmed: 11053506
PLoS Med. 2019 Dec 10;16(12):e1002984
pubmed: 31821329
Br Med Bull. 2003;67:1-11
pubmed: 14711750
Lancet Glob Health. 2016 Nov;4(11):e827-e836
pubmed: 27693439
Lancet. 2016 Jan 30;387(10017):462-74
pubmed: 26584737
J Glob Health. 2016 Dec;6(2):020601
pubmed: 27648256
Bull World Health Organ. 2000;78(5):593-602
pubmed: 10859853
Int J Gynaecol Obstet. 2002 Apr;77(1):67-75
pubmed: 12094777
PLoS One. 2012;7(7):e41114
pubmed: 22844432
BJOG. 2014 Mar;121 Suppl 1:14-24
pubmed: 24641531
Lancet. 2016 Oct 29;388(10056):2164-2175
pubmed: 27642022
Bull World Health Organ. 2013 May 1;91(5):357-67
pubmed: 23678199
Afr J Reprod Health. 2003 Dec;7(3):41-8
pubmed: 15055145
Lancet. 2016 Dec 3;388(10061):2811-2824
pubmed: 27072119
Lancet. 2013 May 18;381(9879):1747-55
pubmed: 23683641